Thomas M Barnes

USPTO Granted Patents = 10 (Patent Applications = 9)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 22(Granted Patents)

Location History:

Boston, MA (US) (2006)
Cambridge, MA (US) (2020)
Brookline, MA (US) (2004 - 2022)

Company Filing History:

4 out of 850

Millennium Pharmaceuticals Limited

patents

3 out of 3

Eleven Biotherapeutics, Inc.

patents

1 out of 4

Ore Pharmaceuticals Inc.

Years Active: 2004-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11459386 - IL-6 antagonists and uses thereof (2022-10-04),

2. 10711050 - Variant serum albumin with improved half-life and other properties (2020-07-14),

3. 9951130 - IL-6 antagonists and uses thereof (2018-04-24),

4. 9458216 - Nucleic acid encoding chimeric IL-1 receptor type I antagonists (2016-10-04),

5. 8853150 - Chimeric IL-1 receptor type I antagonists (2014-10-07),

6. 8003334 - Methods for identifying compounds which bind to TANGO294 (2011-08-23),

7. 7842709 - Method for treating inflammatory diseases of the digestive tract (2010-11-30),

8. 7547766 - Anti-tango294 antibodies and uses thereof (2009-06-16),

9. 7033780 - Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein (2006-04-25),

10. 6764677 - Tango 294, a lipase-like protein (2004-07-20),

Title: The Innovations of Thomas M. Barnes

Introduction

Thomas M. Barnes is a notable inventor based in Brookline, MA (US), recognized for his significant contributions to the field of biotechnology. He holds a total of 10 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his latest patents, Barnes has developed IL-6 antagonists and uses thereof. These antagonists are specifically designed to bind to site II of interleukin-6 (IL-6). The methods disclosed in this patent aim to treat IL-6 related diseases, including conditions affecting the eye, such as diabetic macular edema. Another significant invention by Barnes is a variant serum albumin with improved half-life and other properties. This invention provides methods and materials for creating variant serum albumin amino acid sequences that exhibit enhanced characteristics compared to wild type serum albumin sequences. Furthermore, it includes methods for producing fusion proteins that combine these variant sequences with therapeutic or diagnostic agents, ensuring improved efficacy.

Career Highlights

Throughout his career, Thomas M. Barnes has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Millennium Pharmaceuticals Limited and Eleven Biotherapeutics, Inc. His work in these organizations has contributed to the development of innovative therapies and treatments.

Collaborations

Barnes has collaborated with esteemed colleagues, including John D. Sharp and Michael March Schmidt. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Thomas M. Barnes exemplifies the spirit of innovation in biotechnology through his patents and collaborations. His work continues to impact the medical field positively, paving the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.